User: Guest  Login
Title:

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Document type:
Article; Journal Article
Author(s):
Kapp-Schwoerer, Silke; Weber, Daniela; Corbacioglu, Andrea; Gaidzik, Verena I; Paschka, Peter; Krönke, Jan; Theis, Frauke; Rücker, Frank G; Teleanu, Maria-Veronica; Panina, Ekaterina; Jahn, Nikolaus; Herzig, Julia; Kubanek, Lena; Schrade, Anika; Göhring, Gudrun; Fiedler, Walter; Kindler, Thomas; Schroeder, Thomas; Mayer, Karin T; Lübbert, Michael; Wattad, Mohammed; Götze, Katharina S; Horst, Heinz A; Koller, Elisabeth; Wulf, Gerald; Schleicher, Jan; Bentz, Martin; Krauter, Jürgen; Bullinger, Lar...     »
Abstract:
Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1-mutated (NPM1mut) acute myeloid leukemia (AML) and represents a powerful tool to evaluate treatment effects within clinical trials. We determined NPM1mut transcript levels (TLs) by quantitative reverse-transcription polymerase chain reaction and evaluated the prognostic impact of NPM1mut MRD and the effect of gemtuzumab ozogamicin (GO) on NPM1mut TLs and the cumulative incidence of rel...     »
Journal title abbreviation:
Blood
Year:
2020
Journal volume:
136
Journal issue:
26
Pages contribution:
3041-3050
Fulltext / DOI:
doi:10.1182/blood.2020005998
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/33367545
Print-ISSN:
0006-4971
TUM Institution:
290; III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX